Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1363-1370

  Hansen, Katrine B ^a,b   Vilsbøll, Tina ^a   Bagger, Jonatan I ^a   Holst, Jens J ^b   Knop, Filip K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; PLACEBO; PREDNISOLONE; SODIUM CHLORIDE;

ADULT; ARTICLE; CALORIC INTAKE; CAUCASIAN; CONTROLLED STUDY; GLUCAGON BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE INFUSION; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDENTARY LIFESTYLE;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INCRETINS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; KINETICS; MALE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84859529805     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2594     Document Type: Article

References (42)

1. Reaven GM, Hollenbeck CB, Chen YD 1989 Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 32:52-55 (Pubitemid 19061742)
2. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498 (Pubitemid 16035703)
3. Vilsbøll T, Krarup T, Madsbad S, Holst JJ 2003 Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115-121 (Pubitemid 36773875)
4. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
5. Nauck MA, Baller B, Meier JJ 2004 Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53 Suppl 3:S190-S196 (Pubitemid 39564543)
6. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S 2011 Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34 Suppl 2:S251-S257
7. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S 1987 Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism 36:677-682 (Pubitemid 17100983)
8. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307 (Pubitemid 23037285)
9. Vilsbøll T, Krarup T, Madsbad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45:1111-1119 (Pubitemid 34985287)
10. Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S 2008 Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 51:632-640
11. Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S 2009 Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199-207
12. Kjems LL, Holst JJ, Vølund A, Madsbad S 2003 The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:38038-38036
13. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK 2010 Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 95:3309-3317
14. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK 2011 Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab 96:447-453
15. Fiel SB, Vincken W 2006 Systemic corticosteroid therapy for acute asthma exacerbations. J Asthma 43:321-331 (Pubitemid 43995508)
16. Bablok W, Passing H, Bender R, Schneider B 1988 A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 26:783-790
17. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539 (Pubitemid 24096293)
18. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
19. Ørskov C, Jeppesen J, Madsbad S, Holst JJ 1991 Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423
20. Baldissera FG, Holst JJ 1984 Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia 26:223-228 (Pubitemid 14167805)
21. Holst JJ, Pedersen JH, Baldissera F, Stadil F 1983 Circulating glucagon after total pancreatectomy in man. Diabetologia 25:396-399 (Pubitemid 14235463)
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
23. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470 (Pubitemid 29418240)
24. Kjems LL, Christiansen E, Vølund A, Bergman RN, Madsbad S 2000 Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49:580-588 (Pubitemid 30183746)
25. Kjems LL, Vølund A, Madsbad S 2001 Quantification of β-cell function during IVGTT in type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods. Diabetologia 44:1339-1348 (Pubitemid 33010513)
26. Van Cauter E, Mestrez F, Sturis J, Polonsky KS 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377
27. Pacini G, Mari A 2003 Methods for clinical assessment of insulin sensitivity and β-cell function. Best Pract Res Clin Endocrinol Metab 17:305-322
28. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al 1993 Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663-1672 (Pubitemid 23318125)
29. Wild S, Roglic G, Green A, Sicree R, King H 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053 (Pubitemid 38579764)
30. Ørskov C, Wettergren A, Holst JJ 1996 Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31:665-670 (Pubitemid 26290929)
31. 2+ and amplification signals in β-cells. Diabetes 55:441-451
32. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA 2001 Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497-2504 (Pubitemid 33642767)
33. Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA 2005 Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia 48:1872-1881 (Pubitemid 41317843)
34. Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ 2003 The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897-4903 (Pubitemid 37357541)
35. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T 2007 The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul Pept 144:123-130 (Pubitemid 350030308)
36. Meier JJ, Nauck MA 2010 Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes 59:1117-1125
37. Natali A, Muscelli E, Mari A, Balkau B, Walker M, Tura A, Anderwald C, Golay A, Ferrannini E 2010 Insulin sensitivity and β-cell function in the offspring of type 2 diabetic patients: impact of line of inheritance. J Clin Endocrinol Metab 95:4703-4711
38. Walker M, Mari A, Jayapaul MK, Bennett SM, Ferrannini E 2005 Impaired β-cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects. Diabetologia 48:2470-2476 (Pubitemid 41738209)
39. Faber OK, Binder C 1977 C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus. Diabetes 26:605-610
40. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbøl I, Binder C 1981 Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 210:153-156 (Pubitemid 11018430)
41. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H 1997 Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 40:1439-1448 (Pubitemid 28004938)
42. Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M 2005 Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 54:1168-1173 (Pubitemid 41206877)